Society Citation Award

Awardees

• 

  Kimberly E. Hanson, MD, MHS, FIDSA

  Kimberly E. Hanson, MD, MHS, FIDSA, has spearheaded the development of novel diagnostic approaches to infectious diseases that have significantly improved patient care and outcomes. During the COVID-19 pandemic, Dr. Hanson tirelessly reviewed the avalanche of emerging literature and led the development of diagnostic guidelines to ensure that clinicians had the most accurate and up-to-date information available to diagnose and manage patients. 

  Dr. Hanson is a professor of medicine and pathology at the University of Utah and director of the Immunocompromised Host Infectious Diseases Service at the University of Utah. She is also director of the Mycology Section within Associated Regional and University Pathologists Laboratories, a national nonprofit and academic reference laboratory at the forefront of diagnostic medicine. In her research, Dr. Hanson focuses on designing and conducting multicenter interventional trials to assess the impact of new infectious diseases tests for opportunistic infections on outcomes that matter to patients.  

  As a guiding member of Utah’s COVID-19 response team, Dr. Hanson played a pivotal role in overseeing clinical testing, conducting prospective surveillance studies and spearheading specimen comparison studies for SARS-CoV-2 detection. Her work has been instrumental in establishing the utility of saliva as a specimen for COVID-19 testing, evaluating the performance of self-collected swabs versus swabs collected by health care workers and determining the efficacy of point-of-care antigen testing in asymptomatic people.  

  Dr. Hanson took the lead in authoring IDSA’s first COVID-19 diagnostic guidelines for molecular diagnostic, antigen and serologic testing, employing the rigorous Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology as a systematic approach for making clinical practice recommendations. She spent many hours reviewing literature and working with colleagues to develop a consensus for the panel’s recommendations.  

  A member of IDSA’s Diagnostic Test Committee and Board of Directors, Dr. Hanson worked with staff participating in meetings with members of Congress to advocate for legislation targeted for action by IDSA. She continues to serve IDSA as a deputy editor of Clinical Infectious Diseases. Her expertise is widely recognized within the academic community. 

  An exemplary role model to faculty and trainees in infectious diseases, Dr. Hanson has also facilitated opportunities within IDSA for colleagues who might have felt out of reach without her mentorship.   

  IDSA is pleased to recognize Dr. Hanson’s contributions to innovative diagnostic approaches to infectious diseases with a 2024 Society Citation Award. 

• 

  Michelle D. Collins-Ogle, MD, FAAP, FPIDS

  Michelle D. Collins-Ogle, MD, FAAP, FPIDS, is a fierce advocate for youth and adolescents with or at risk of HIV, especially transgender youth and adolescents, and a leader in providing compassionate gender-affirming care to these patients. She serves as a voice for this often voiceless and unseen community, even in the rural North Carolina Bible Belt. 

  Dr. Collins-Ogle is medical director of the Montefiore Adolescent and Youth Sexual Health Clinic, an attending pediatrician in infectious diseases and adolescent medicine at the Children’s Hospital at Montefiore, and an associate professor of pediatrics at Albert Einstein College of Medicine. The Montefiore Adolescent and Youth Sexual Health Clinic provides comprehensive medical care for youth, adolescents and young adults with HIV/AIDS.   

  Before joining Montefiore, Dr. Collins-Ogle was director of infectious diseases for the Warren-Vance Community Health Center in North Carolina. She built a clinic that became a welcoming home for transgender people, a largely marginalized population facing stigma, poverty, homophobia and racism in the rural South. Her compassion drew transgender people to her clinic.  

  In Washington, D.C., Dr. Collins-Ogle advocates for funding for clinics that create medical homes for marginalized populations with HIV as co-chair of the Ryan White Medical Providers Coalition’s Steering Committee. When her patients were losing access to their antiretroviral therapy due to a rigid state interpretation of eligibility requirements for the AIDS Drug Assistance Program, she urged federal funders at the Health Resources and Services Administration’s HIV/AIDS Bureau to clarify the requirements. After much persistence, the HIV/AIDS Bureau produced new guidance, and patients were able to access antiretroviral therapy. 

  Dr. Collins-Ogle is the vice chair of the Board of Directors of the American Academy of HIV Medicine. She served as the pediatric liaison for the Pediatric Infectious Diseases Society and the HIV Medicine Association and as a member of the Presidential Advisory Council on HIV/AIDS during the Obama Administration. Dr. Collins-Ogle received the Linda Bell Award for Advocacy in HIV/AIDS from the North Carolina Community AIDS Fund. 

  For her leadership in advocating for and providing optimal care for trans youth and adolescents with or at risk of HIV, IDSA is delighted to recognize Dr. Collins-Ogle with a 2024 Society Citation Award. 

• 

  William G. Powderly, MD, FIDSA

  William G. Powderly, MD, FIDSA, was one of the first generation of infectious diseases physicians to embrace the care of people with HIV and was the founding chair of the HIV Medicine Association, and subsequently the first president of IDSA to come from that generation of HIV physicians. 

  Dr. Powderly is the Dr. J. William Campbell Professor of Medicine and the Larry J. Shapiro Director of the Institute for Public Health at Washington University School of Medicine in St. Louis. He is also associate dean for clinical and translational science and director of the Institute of Clinical and Translational Science there, and co-director of the Division of Infectious Diseases. Dr. Powderly also previously served as dean of medicine and head of the School of Medicine at University College Dublin in Ireland. Dr. Powderly is a fellow of the Royal College of Physicians in Ireland, the Royal College of Physicians (London) and the American Association for the Advancement of Science.  

  For more than 30 years, Dr. Powderly has conducted HIV-related clinical research, much of it funded by NIH. His research has focused on opportunistic infections (especially fungal infections), metabolic complications and long-term outcomes of antiretroviral therapy. Dr. Powderly is the author of more than 500 articles, reviews and book chapters. He has been a member of many advisory groups on HIV and infectious diseases for NIH, CDC, the Canadian Institute for Health Research and the European Medicines Agency. As director of the Institute for Public Health at Washington University, Dr. Powderly has led the institute to focus on implementation science, community partnerships, economic and policy research, and global health to broaden the impact of discovery science and to address disparities in health outcomes. More recently, he oversaw Washington University’s clinical and translational research response to SARS-CoV-2 and was lead principal investigator for NIH’s ACTIV trials of immunomodulators in the treatment of severe COVID-19.  

  Dr. Powderly chaired IDSA’s HIV Committee and led its transition to the HIV Medicine Association, serving as the inaugural chair of HIVMA. He was president of IDSA and a member of the Board of Directors and the Fellowship Program Directors Committee. During his presidency, Dr. Powderly implemented changes to diversify the leadership of the organization. As a result, IDSA’s leaders now more closely reflect the Society’s membership. 

  For his leadership in HIV care and research and his contributions to IDSA and HIVMA, the Society is proud to honor Dr. Powderly with a 2024 Society Citation Award.